Unknown

Dataset Information

0

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy.


ABSTRACT: The aim of this study was to evaluate the outcomes of patients with advanced or recurrent ovarian cancer treated with cisplatin combined with topotecan as second- or higher-line palliative chemotherapy.We retrospectively reviewed the medical records of patients with advanced or recurrent ovarian cancer, who were treated with cisplatin (50?mg/m on day 1) and topotecan (0.75?mg/m on days 1-3). Treatment response, progression-free survival (PFS) and overall survival (OS) were analyzed, and laboratory data were reviewed to evaluate toxicities.Thirty one patients were treated with cisplatin and topotecan. The objective response rate (ORR) was 22.6%, and the disease control rate (DCR) was 61.3%. The median PFS was 3.7 months (95% confidence interval [CI], 2.3-5.2 months) and the median OS was 44.5 months (95% CI, 35.5-53.5 months). The ORR (33.3% vs. 0%; P = .012) was significantly better in the platinum-sensitive group compared to the platinum-resistant group. The median PFS was significantly longer in the platinum-sensitive group compared to the platinum-resistant group (7.7 vs 2.5 months; P?

SUBMITTER: Lee MW 

PROVIDER: S-EPMC7440193 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy.

Lee Myung-Won MW   Ryu Hyewon H   Song Ik-Chan IC   Yun Hwan-Jung HJ   Jo Deog-Yeon DY   Ko Young Bok YB   Lee Hyo-Jin HJ  

Medicine 20200401 17


The aim of this study was to evaluate the outcomes of patients with advanced or recurrent ovarian cancer treated with cisplatin combined with topotecan as second- or higher-line palliative chemotherapy.We retrospectively reviewed the medical records of patients with advanced or recurrent ovarian cancer, who were treated with cisplatin (50 mg/m on day 1) and topotecan (0.75 mg/m on days 1-3). Treatment response, progression-free survival (PFS) and overall survival (OS) were analyzed, and laborato  ...[more]

Similar Datasets

| S-EPMC7016399 | biostudies-literature
| S-EPMC7397908 | biostudies-literature
| S-EPMC5580234 | biostudies-literature
| S-EPMC5868151 | biostudies-literature
| S-EPMC3870479 | biostudies-literature
| S-EPMC4317911 | biostudies-literature
| S-EPMC5665721 | biostudies-other
| S-EPMC4988994 | biostudies-literature
| S-EPMC7050081 | biostudies-literature
| S-EPMC6035193 | biostudies-literature